deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05693181

Cord Blood Cells in Patients With Acute SCI (SUBSCI II)

Systemic Administration of Allogenic Mononuclear Cord Blood Cells in Patients With Acute Severe Contusion Spinal Cord Injury: Safety and Efficiency Evaluation, Stages I/II

Sponsor: K.L. Hetagurov North-Osetian State University

Conditions Spinal Cord Injury, Acute
Interventions Control vehicle (sterile saline) Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
Updated 5 times since 2023 Last updated: Jan 12, 2023 Started: Dec 5, 2022 Primary completion: Dec 31, 2024 Completion: Aug 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Spinal Cord Injury, Acute and is currently ongoing. K.L. Hetagurov North-Osetian State University leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshotRecruiting~Oct 2025 – present · 11 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Oct 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Recruiting → Unknown

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Feb 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • K.L. Hetagurov North-Osetian State University
  • Sklifosovsky Institute of Emergency Care
  • State-Financed Health Facility Samara Regional Medical Center Dinasty
Data source: Sklifosovsky Institute of Emergency Care

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations